NeuShen Therapeutics

NeuShen Therapeutics, a Sino-US biopharmaceutical company, has entered into a licensing agreement with Livzon Pharmaceutical Group Inc. (HKG: 1513), a Chinese pharmaceutical firm. The agreement grants Livzon exclusive rights and interests to NeuShen’s small molecule NS-041 in Greater China. NeuShen will retain the lead role in the development and commercialization…